Gillette, McLaren Mercedes enhance official partnership
LONDON — Procter & Gamble’s Gillette brand is enhancing its collaboration with McLaren Mercedes to bring to life a marketing campaign focused on Precision Engineering.
The partnership covers Europe, Middle East and Africa. Gillette and McLaren are coming together for a new marketing campaign emphasizing the ways the two brands push boundaries of technology.
As the ultimate male grooming and high-technology experts, Gillette and McLaren are constantly innovating to achieve greater precision and enhanced performance. Gillette ushered in the era of modern shaving, and for 110 years constantly reinvented the shaving category. McLaren pioneered the first carbon fibre chassis in Formula 1 and introduced advanced electronic systems leading to decades of groundbreaking achievements on the track, the companies stated.
This passion will be further leveraged through a sports marketing campaign that aims to reach and inspire millions of men via TV, digital, PR and In-store programs. McLaren Mercedes F1 drivers Jenson Button and Kevin Magnussen will engage men’s passion for Formula 1 and Gillette grooming technology.
Actavis enters into agreement with Mylan, Famy Care regarding generic Generess FE
DUBLIN — Actavis on Tuesday announced that it has entered into an agreement with Mylan and Famy Care to settle all outstanding patent litigation related to Mylan’s generic version of Generess FE (norethindrone, ethinyl estradiol and ferrous fumarate chewable tablets).
Under the terms of the agreement, Actavis will grant Mylan a license to market its generic version of Generess FE under its pending abbreviated new drug application beginning on April 1, 2015.
Alternatively, Mylan will be permitted to launch an authorized generic version of Actavis’ product beginning on October 1, 2015. Other terms of the settlement were not disclosed. Actavis remains in litigation with Lupin Ltd. in connection with Lupin’s pending ANDA for a generic version of Generess.
Mylan gains U.S., Canada rights to proposed generic equivalents of Flixotide and Flovent
OXFORD, England — Prosonix, a speciality pharmaceutical company developing a portfolio of inhaled respiratory medicines by Design, on Tuesday announced that it has entered into a global licensing agreement with Mylan for its leading inhaled respiratory products, PSX1001 and PSX1050.
PSX1001 and PSX1050, which are the first products to emerge from Prosonix’s proprietary particle engineering platform, are being developed as generic versions to GlaxoSmithKline’s pressurised metered dose inhalers Flixotide and Flovent, respectively. Flixotide and Flovent contain the active ingredient fluticasone propionate, a potent inhaled corticosteroid, and are indicated for the treatment of asthma.
According to IMS Health, Flixotide and Flovent had global brand sales of approximately $1.3 billion for the 12 months ended Dec. 31, 2013. A first marketing authorisation application for PSX1001 is expected to be submitted in the European Union in 2014.
Under the terms of the licensing agreement, Prosonix will file PSX1001 in the EU and retain marketing rights in certain territories. Mylan has marketing rights for PSX1001 and PSX1050 in the U.S., Canada, Australia, New Zealand, India, Japan, the EU, Iceland, Liechtenstein, Norway, Switzerland, Turkey, Russian Federation and the Commonwealth of Independent States. All other terms of the agreement remain confidential.